Nakanishi Inc.

DB:6SN Stock Report

Market Cap: €1.2b

Nakanishi Valuation

Is 6SN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6SN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6SN (€14) is trading below our estimate of fair value (€22.38)

Significantly Below Fair Value: 6SN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6SN?

Key metric: As 6SN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6SN. This is calculated by dividing 6SN's market cap by their current earnings.
What is 6SN's PE Ratio?
PE Ratio22.4x
EarningsJP¥8.68b
Market CapJP¥194.34b

Price to Earnings Ratio vs Peers

How does 6SN's PE Ratio compare to its peers?

The above table shows the PE ratio for 6SN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.7x
EUZ Eckert & Ziegler
24.5x5.9%€879.3m
DRW3 Drägerwerk KGaA
7.2x2.0%€798.0m
AFX Carl Zeiss Meditec
25.4x16.3%€5.2b
SBS Stratec
33.6x25.4%€336.7m
6SN Nakanishi
22.4x10.4%€194.3b

Price-To-Earnings vs Peers: 6SN is good value based on its Price-To-Earnings Ratio (22.4x) compared to the peer average (22.7x).

Price to Earnings Ratio vs Industry

How does 6SN's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
6SN 22.4xIndustry Avg. 29.7xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 6SN is good value based on its Price-To-Earnings Ratio (22.4x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is 6SN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6SN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.4x
Fair PE Ratio19.4x

Price-To-Earnings vs Fair Ratio: 6SN is expensive based on its Price-To-Earnings Ratio (22.4x) compared to the estimated Fair Price-To-Earnings Ratio (19.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6SN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€14.00
€19.64
+40.3%
13.7%€23.46€16.67n/a5
Nov ’25€15.70
€20.10
+28.0%
13.7%€24.02€17.06n/a5
Oct ’25€16.40
€20.10
+22.5%
13.7%€24.02€17.06n/a5
Sep ’25€16.00
€19.16
+19.8%
14.0%€23.34€15.97n/a5
Aug ’25€15.10
€18.56
+22.9%
15.8%€23.49€15.27n/a5
Jul ’25€14.50
€18.56
+28.0%
15.8%€23.49€15.27n/a5
Jun ’25€13.40
€18.56
+38.5%
15.8%€23.49€15.27n/a5
May ’25€14.20
€20.21
+42.3%
13.1%€23.27€15.92n/a5
Apr ’25€14.30
€20.21
+41.3%
13.1%€23.27€15.92n/a5
Mar ’25€14.50
€22.60
+55.9%
17.9%€27.66€16.35n/a4
Feb ’25€15.10
€22.60
+49.7%
17.9%€27.66€16.35n/a4
Jan ’25€15.20
€23.92
+57.3%
8.5%€26.80€22.41n/a3
Dec ’24€14.70
€23.92
+62.7%
8.5%€26.80€22.41n/a3
Nov ’24€20.80
€25.63
+23.2%
7.3%€27.78€23.23€15.703
Oct ’24€22.00
€25.63
+16.5%
7.3%€27.78€23.23€16.403
Sep ’24€22.80
€24.28
+6.5%
5.1%€26.01€23.35€16.003
Aug ’24€21.00
€25.30
+20.5%
3.9%€26.68€24.54€15.103
Jul ’24€20.00
€25.30
+26.5%
3.9%€26.68€24.54€14.503
Jun ’24€19.50
€25.30
+29.7%
3.9%€26.68€24.54€13.403
May ’24€17.20
€24.93
+44.9%
5.7%€26.93€23.75€14.203
Apr ’24€18.00
€24.93
+38.5%
5.7%€26.93€23.75€14.303
Mar ’24€19.50
€24.93
+27.8%
5.7%€26.93€23.75€14.503
Feb ’24€19.10
€24.93
+30.5%
5.7%€26.93€23.75€15.103
Jan ’24€18.10
€24.93
+37.7%
5.7%€26.93€23.75€15.203
Dec ’23€19.80
€24.45
+23.5%
6.5%€26.67€23.16€14.703
Nov ’23€18.50
€24.45
+32.1%
6.5%€26.67€23.16€20.803

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%